|
ZA978515B
(en)
*
|
1996-09-23 |
1999-03-23 |
Lilly Co Eli |
Intermediates and process for preparing olanzapine
|
|
US6617321B2
(en)
|
1997-09-30 |
2003-09-09 |
Eli Lilly And Company |
2-methyl-thieno-benzodiazepine formulation
|
|
EP1119359B1
(en)
*
|
1998-09-30 |
2004-05-26 |
Eli Lilly & Company |
2-methyl-thieno-benzodiazepine formulation
|
|
CA2395774C
(en)
*
|
1999-12-28 |
2009-09-15 |
Cipla Limited |
New polymorphic forms of olanzapine
|
|
US7022698B2
(en)
|
1999-12-28 |
2006-04-04 |
U & I Pharmaceuticals, Ltd. |
Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
|
|
IL154688A0
(en)
*
|
2000-08-31 |
2003-09-17 |
Reddys Lab Ltd Dr |
Hydrates of olanzapine and processes for the preparation thereof
|
|
US6740753B2
(en)
|
2001-01-04 |
2004-05-25 |
Geneva Pharmaceuticals, Inc. |
Olanzapine crystal modification
|
|
WO2003037903A1
(en)
*
|
2001-10-29 |
2003-05-08 |
Dr. Reddy's Laboratories Ltd. |
Olanzapine dihydrate-ii a process for its preparation and use thereof
|
|
DE60336226D1
(de)
|
2002-05-31 |
2011-04-14 |
Sandoz Ag |
Verfahren zur herstellung von olanzapin form i
|
|
SI21270A
(sl)
|
2002-07-15 |
2004-02-29 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Kristalne oblike olanzapina in postopki za njihovo pripravo
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
WO2004058773A1
(en)
*
|
2002-12-24 |
2004-07-15 |
Teva Pharmaceutical Industries Ltd. |
Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
|
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
|
EP1684734A2
(en)
*
|
2003-11-18 |
2006-08-02 |
3M Innovative Properties Company |
Olanzapine containing transdermal drug delivery compositions
|
|
EP1709053B1
(en)
|
2004-01-27 |
2011-04-06 |
Synthon B.V. |
Stable salts of olanzapine
|
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
|
DE102004033670A1
(de)
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
|
US20080009481A1
(en)
*
|
2004-07-14 |
2008-01-10 |
Shasun Chemicals And Drugs Limited |
Process For Making Form I Of Olanzapine
|
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
EP1630163A1
(de)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
ES2303462B1
(es)
|
2004-09-06 |
2009-06-05 |
Shasun Chemicals And Drugs Limited |
Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
|
|
KR101381454B1
(ko)
|
2004-09-29 |
2014-04-04 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
US7910577B2
(en)
*
|
2004-11-16 |
2011-03-22 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
|
DE102004058337A1
(de)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
|
PL1838716T3
(pl)
|
2005-01-05 |
2011-09-30 |
Lilly Co Eli |
Dihydrat embonianu olanzapiny
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
WO2007067714A2
(en)
*
|
2005-12-08 |
2007-06-14 |
The Mclean Hospital Corporation |
Treatment of sequelae of psychiatric disorders
|
|
US7834176B2
(en)
*
|
2006-01-26 |
2010-11-16 |
Sandoz Ag |
Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
|
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
MX2008014024A
(es)
|
2006-05-04 |
2008-11-14 |
Boehringer Ingelheim Int |
Formas poliformas.
|
|
AR062927A1
(es)
|
2006-10-11 |
2008-12-17 |
Bayer Healthcare Ag |
4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
|
|
US8039461B1
(en)
|
2006-11-10 |
2011-10-18 |
Pisgah Laboratories, Inc. |
Physical states of a pharmaceutical drug substance
|
|
US7718649B1
(en)
|
2006-11-10 |
2010-05-18 |
Pisgah Labs, Inc. |
Physical states of a pharmaceutical drug substance
|
|
EP2185559A1
(en)
|
2007-08-03 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Crystalline form of a dihydropteridione derivative
|
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
US8883863B1
(en)
|
2008-04-03 |
2014-11-11 |
Pisgah Laboratories, Inc. |
Safety of psuedoephedrine drug products
|
|
EP2299983A4
(en)
*
|
2008-07-24 |
2012-10-10 |
Handa Pharmaceuticals Llc |
ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED
|
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
CN102149407A
(zh)
|
2008-09-10 |
2011-08-10 |
贝林格尔.英格海姆国际有限公司 |
治疗糖尿病和相关病症的组合疗法
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
CN107011345A
(zh)
|
2008-12-23 |
2017-08-04 |
勃林格殷格翰国际有限公司 |
有机化合物的盐形式
|
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
|
EP2504002B1
(en)
|
2009-11-27 |
2019-10-09 |
Boehringer Ingelheim International GmbH |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
|
KR101927068B1
(ko)
|
2010-05-05 |
2018-12-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
|
|
KR20200028498A
(ko)
|
2010-06-24 |
2020-03-16 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
|
HUE061596T2
(hu)
|
2011-07-15 |
2023-07-28 |
Boehringer Ingelheim Int |
Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US20130303462A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
|
|
ES2929025T3
(es)
|
2012-05-14 |
2022-11-24 |
Boehringer Ingelheim Int |
Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
|
JP2016027003A
(ja)
*
|
2012-11-20 |
2016-02-18 |
大蔵製薬株式会社 |
長期間安定なオランザピンの水性医薬製剤
|
|
WO2015011236A1
(en)
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Treatment of myelodysplastic syndrome
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
|
BR112018072401A2
(pt)
|
2016-06-10 |
2019-02-19 |
Boehringer Ingelheim International Gmbh |
combinações de linagliptina e metformina
|